Midhun Korrapati, PhD DABT ERT

Experience

• 

  University of Louisiana Monroe

  Jan 2002 - Dec 2006

  Research Assistant (Toxicology)

  Responsibilities: Designed and conducted toxicology studies dealing with understanding the mechanisms of kidney injury and repair; and the role of toxicokinetics in development of toxicant-induced liver injury.Critically interpreted data, documented/reported data, research proposal writing (NIH RO1s and renewals), writing manuscripts, scientific presentation, developed research projects, developed methods, participated in collaborative research projects, trained and supervised junior graduate students. Specific achievements:Identified, analyzed and validated disease-associated candidate biomarkers and key molecular mechanisms/signaling pathways involved in injury and repair after toxicant-induced nephrotoxicity and acute kidney injury in mice using proteomics. Show less

• 

  The National Institutes of Health

  Feb 2007 - Jul 2011

  Postdoctoral Scientist (Mechanistic & Investigative Toxicology)

  Responsibilities: Designed, conducted, interpreted, communicated, reported and managed multiple hypothesis-driven investigative toxicology projects to understand the molecular and cellular basis of immune-mediated idiosyncratic Drug-Induced Liver Injury (DILI) with special interest in Acetaminophen (Tylenol) and Halothane-induced hepatotoxicity to identify potential risk factors in determining susceptibility of patients to DILI.Developed research projects and methods; Established and maintained collaborations with multiple research teams and core facilities; Trained/supervised students and postdoctoral scientists.Specific achievements: Discovered a novel mechanism of protection against Acetaminophen-induced hepatotoxicity in mice.Identified novel signaling pathways of mitochondrial/endoplasmic reticulum stress-response and autophagy in an animal model of halothane-induced hepatotoxicity; Identified several new mitochondrial and endoplasmic reticulum stress biomarkers/susceptibility candidates for liver injury in an animal model of halothane-induced liver toxicity using proteomics. Show less

• 

  Medical University of South Carolina

  Jul 2011 - Jul 2014

  Staff Scientist (Translational Research & Biomarkers)

  Responsibilities:Collaborate with multidisciplinary team of scientists and manage multiple projects of developing small animal models of diseases (acute kidney injury, diabetic nephropathy, skeletal muscle atrophy, Huntington’s, Alzheimer’s and Parkinson’s); Investigative the mechanisms of disease progression to identify novel targets; and support the goals of project teams in a matrixed environment and evaluate safety/efficacy for new investigational compounds in these animal models of diseases.Identification and development of novel urinary biomarkers of acute kidney injury (AKI) and diabetic nephropathy in animal models and translate the findings to clinical settings.Preparation and review of study protocols, reports and manuscripts, regulatory submissions (IACUC, IRB, IND), participation in toxicology and pharmacology initiatives and other active cross-functional collaborations. Provide technical expertise and oversight to other research staff members and delegate work amongst the various staff.Specific achievements: Discovered new indication for investigational compounds in accelerating recovery from toxicant-induced AKI, diabetic nephropathy and muscle atrophy in animal models, and investigated the mechanisms of their protection.Reviewed and compiled safety data for submission of Suramin-IND application to the FDA; Collaborate with clinicians to organize clinical trials for Suramin in patients with AKI and diabetic nephropathy.Identified novel urinary early predictive biomarkers of diabetic nephropathy in an animal model by using cutting-edge LC-MS/MS-based proteomics; Identified a novel urinary biomarker for renal mitochondrial dysfunction in an animal model of kidney injury and validated in patients who developed AKI after cardiac surgery. Show less

• 

  INDIGO Biosciences, INC

  Jul 2014 - Dec 2016

  Senior Scientist/Study Manager (Preclinical Discovery Toxicology)

  Responsibilities: Primary roles are to design and plan Toxicology Pathway screens, Drug-Drug Interaction screens and Phenotypic screening; Design Metabolic disease-specific Safety Pharmacology studies; and Developing novel screening assays for Mitochondrial Toxicity for clients, train and manage research staff, present high quality reports to clients on time, provide scientific and technical expertise to clients.Develop new assays in Investigative/Mechanistic toxicology area; provide scientific expertise in various stages of product development, evaluation of literature, and collaborating/communicating with experts in the field to generate sound expectations and to resolve issues.Specific accomplishments: Developed novel assays for the rapid in vitro assessment of drug-induced mitochondrial toxicity in treated cells. Authored several study reports and demonstrated success in providing quality screening services in Discovery and Investigative Toxicology to clients within the pharmaceutical, biotechnology, food, agriculture and nutriceutical industries, government research agencies, as well as to academic researchers. Show less

• 

  GSK

  Dec 2016 - Sept 2021

  Toxicologist - Non-Clinical Safety

  Responsibilities: • Serve as a project toxicologist and support safety assessment of small molecules and biopharmaceuticals in different research units across GSK pharmaceuticals.• Design, conduct, integrated data interpretation and reporting of general toxicology, investigative and model development studies; and contribute to project issue resolution activities. • Contribute as appropriate to external study monitoring activities and ensure that studies and related activities are carried out in compliance with applicable guidelines and regulations. • Serve as an author in GSK’s Target Safety and Off-Target Safety Review core committees and contribute as a SME/consultant in Nonclinical Safety Panels and Attrition Reduction Teams providing expert consultant advice on non-clinical data and strategy to project teams. • Serve as GSK representative for external/academic collaborations to develop novel immune-mediated liver injury modelsSpecific accomplishments: • Published 44 nonclinical reports and summarized toxicology findings for IB and IND documents.• 2020 GlaxoSmithKline Teamwork Award• 2019 GlaxoSmithKline Innovation Award • Authored target and off-target safety reviews for 24 different novel targets to project teams in early discovery stage or that have reached pre-CS or beyond.• SME on Hepatic Safety Panel and Attrition Reduction Teams and provided strategies to mitigate DILI risk for relevant workstreams, developed data-based strategy and guidance for project teams and advise on strategy for lead optimisation up to pre-CS.• GSK representative in external collaborations (GSK-Sanofi-NC3R companies; GSK-Phoenix Bío companies; and GSK-Liverpool University, UK) to develop immunologically-competent in vitro and in vivo liver injury models of idiosyncratic DILI. Show less

• 

  Merck

  Sept 2021 - now

  Associate Principal Scientist, Toxicology - Non-Clinical Drug Safety